| Therapeutic | Pateclizumab |
| Target | LTA |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK |
| 100% seqID Fv Structure | 4mxv [Fvs: FE, HL, YX], 4mxw [Fvs: HL, WV] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4mxv [Fvs: FE, HL, YX] |
| 100% seqID Structure | 4mxw [Fvs: HL, WV] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Discontinued |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2011 |
| INN Year Recommended | 2012 |
| Companies Involved | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Rheumatoid arthritis |
| Notes |
